Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CTOR with free AI briefings, catalyst countdowns, and dilution alerts.

CTOR · CITIUS ONCOLOGY, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$16.6M Cash on Hand
15.2mo Cash Runway
Follow CTOR by email Get an email when CTOR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CTOR, unsubscribe in one click. Privacy

📣 What CTOR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Denileukin Diftitox (E7777)
FDA approved Aug 2024 · Lymphir
Persistent or Recurrent Cutaneous T-Cell Lymphoma Phase 3 · NCT01871727 Completed
Combination - CITI-002 (high dose) Hemorrhoids Phase 2 · NCT05348200 Completed

Also used in these trials (approved or third-party drugs, not CTOR's own candidates): Hydrocortisone Acetate, Lidocaine Hydrochloride, Lidocaine, Halobetasol Propionate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CTOR holds $16.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.3M/quarter from operations, an estimated runway of 15.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 50 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CTOR files for a raise →

👥 Who Owns CTOR

Insiders 6.6% Other 5%+ holders 71% Institutions (23 holders) 15.1% Public and other holders 7.3%
HolderTypeShares% of sharesAs of
Citius Pharmaceuticals, Inc. 5%+ holder (13D) 66,049,615 71.04% 2026-05-15
Armistice Capital, LLC Institution (13G, 5%+) 9,394,202 10.10% 2026-09-30
Leonard L Mazur
Chief Executive Officer, Director · +5.50M options
Insider 1,700,000 1.83% 2026-11-09
Myron Z Holubiak
Secretary, Director · +1.60M options
Insider 950,000 1.02% 2026-11-09
Jaime Bartushak
Chief Financial Officer · +2.20M options
Insider 825,000 0.89% 2026-11-09
Myron Czuczman
Chief Medical Officer · +2.20M options
Insider 825,000 0.89% 2026-11-09
Joel David Mayersohn
Director · +375,000 options
Insider 321,228 0.35% 2026-11-12
Eugene Myron Holuka
Director · +400,000 options
Insider 300,000 0.32% 2026-11-12
Carol Webb
Director · +400,000 options
Insider 300,000 0.32% 2026-11-12
Robert Joseph Smith
Director · +250,000 options
Insider 300,000 0.32% 2026-11-12
Dennis M Mcgrath
Director · +400,000 options
Insider 300,000 0.32% 2026-11-12
Suren G Dutia
Director · +400,000 options
Insider 300,000 0.32% 2026-11-12

Share count 92,981,204 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CTOR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CTOR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.